PPARG and cancer: In vitro and in vivo studies have demonstrated anti-proliferative and pro-apoptotic actions of PPARγ agonists such as 15-deoxy-∆-12,14-prostaglandin J2 (15dPG-J2) and thiazolidinediones (TZDs) [104,105], suggesting that PPARγ could be a promising target for cancer therapy.